Kures Therapeutics

Kures Therapeutics is a life sciences company spun out of Columbia University that is developing KUR-101 for the treatment of OUD and acute pain. KUR-101 is a deuterated derivative of mitragynine, the primary alkaloid in kratom leaves, which is a relatively low-potency mu-opioid receptor (MOR) agonist. It is a semi-synthetically produced active pharmaceutical ingredient designed to enhance the safety and potential efficacy of mitragynine. In our preclinical studies conducted to date, KUR-101 has demonstrated dose-dependent analgesic effects in animal models without causing significant respiratory depression at therapeutic doses.